Shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) ended Tuesday session in red amid volatile trading. The shares closed down -1.08 points or -3.77% at $27.53 with 21.60 million shares getting traded. Post opening the session at $28.34, the shares hit an intraday low of $27.35 and an intraday high of $28.59 and the price vacillated in this range throughout the day. The company has a market cap of $9.59 billion and the numbers of outstanding shares have been calculated to be 341.19 million shares.
On Sept. 6, 2016 Valeant Pharmaceuticals International, Inc. (VRX) and Progenics Pharmaceuticals, Inc. (PGNX) announced the U.S. commercial launch of RELISTOR® (methylnaltrexone bromide) Tablets, which is now available for prescribing. RELISTOR Tablets (450 mg once daily) were approved by the U.S. Food and Drug Administration (FDA) for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain on July 19, 2016 .
“We are very pleased to launch RELISTOR Tablets in the U.S. and provide an exceptional new treatment option for the millions of patients who suffer from extreme discomfort due to OIC,” said Joseph C. Papa , Chief Executive Officer of Valeant. “This new method of delivery for RELISTOR offers healthcare professionals a novel alternative to address the treatment of OIC – a growing need in pain management – and demonstrates Valeant’s continued commitment to delivering innovative products that improve people’s lives.”
Shares of EXACT Sciences Corporation (NASDAQ:EXAS) ended Tuesday session in red amid volatile trading. The shares closed down -0.36 points or -1.89% at $18.71 with 2.30 million shares getting traded. Post opening the session at $18.85, the shares hit an intraday low of $18.45 and an intraday high of $19.06 and the price vacillated in this range throughout the day. The company has a market cap of $2.02 billion and the numbers of outstanding shares have been calculated to be 106.77 million shares.
EXACT Sciences Corporation (EXAS) on Aug. 11, 2016 announced that Health Care Service Corp. (HCSC), the nation’s fourth largest health insurer, and Florida Blue recently updated their medical policies to cover Cologuard. With these policy updates, 80 million people are insured by commercial plans with positive medical policies regarding Cologuard. Including Medicare, Cologuard is now covered for 62 percent of its total target population.
“We are pleased that Cologuard’s commercial coverage continues to broaden following its inclusion in the recently-updated U.S. Preventive Services Task Force colorectal cancer screening recommendations,” said Kevin Conroy, chairman and CEO of Exact Sciences. “As health plans continue to update their coverage policies to include Cologuard, an increasing number of people have access to an innovative, non-invasive colorectal cancer screening option.”